Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda plus chemotherapy vs chemotherapy in first-line advanced biliary tract cancer
CTR20192713Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in biliary cancer, sponsored by Merck & Co.. Started May 2020; status: completed.
02
Drugs
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20192713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192713.